Castleman disease mimicking systemic lupus erythematosus: A case report

Rationale: Castleman disease (CD) is a nonclonal lymphoproliferative disorder sometimes manifested systemic inflammatory symptoms. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized with multi-system involvement as well as broad spectrum of serum autoantibodies. When these two conditions happened to have similar clinical spectrum features, the confusion with each other occurred. Patient Concerns: A 46-year-old man suffered from chronic fever, nephrotic syndrome, acute kidney injury, anemia, thrombocytopenia and serositis, as well as hypocomplementemia and negative anti-nuclear antibody. Diagnoses: Meeting the classification criteria for SLE, the patient was diagnosed as SLE at first. The renal biopsy showed that he had endocapillary proliferative glomerulonephritis with negative immunofluorescence. Finally, he was diagnosed with CD after lymph nodes biopsy. Interventions: The patient was treated with oral prednisone (50 mg daily) but got poor response. After being proved to have CD, he was treated with CHOP chemotherapy. Outcomes: His condition was controlled by CHOP chemotherapy. After six course of chemotherapy, the proteinuria disappeared. Lessons: If patients, even qualified by classification criteria of SLE, had negative autoantibody or unsatisfied response to the standard treatment, the original diagnosis should be suspected. The biopsy may be help to identify the final criminals, such as CD.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Related Links:

Purpose: Synchronous chemotherapy with mitomycin C and 5-FU with radiotherapy may have an additional benefit over radiotherapy alone [1]. We looked into the rate of recurrence and median overall survival between these two groups of patients.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The use of FDG PET has become more readily available over the past 15 years. It can be used to aid initial staging of testicular tumours and also assess the response to treatment in the metastatic setting, especially as residual masses are frequently seen after chemotherapy. There have been some recent concerns that FDG PET used to assess for residual disease may have a low positive predictive value [1]. A retrospective audit was carried out to look at the performance of FDG PET in seminoma patients treated at the Edinburgh Cancer Centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The STAMPEDE trial has recently shown a benefit in overall survival by irradiating the prostate of patients with newly diagnosed metastatic prostate cancer [1]. This benefit was only shown in patients with low burden of metastatic disease, as per the CHAARTED criteria [2]. The current standard of care for these patients is androgen deprivation therapy ± docetaxel chemotherapy and radiotherapy to symptomatic areas of disease if required. The aim of this audit is to determine the potential number of men with low burden of metastatic disease who may require additional radiotherapy.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Authors: Gökaslan S, Demirbaş H, Özer Gökaslan Ç Abstract BACKGROUND/AIM: Multiple sclerosis (MS) is an autoimmune disease characterized by neurodegeneration or demyelination, and the relapsing?remitting phase of MS is characterized by acute exacerbation of disease activity. The most commonly used non-invasive approach to assess autonomic function is the determination of heart rate turbulence (HRT) and heart rate variability (HRV). The aim of this study was to evaluate the presence of cardiovascular autonomic dysfunction using HRT and HRV parameters determined via 24-hour Holter ECG monitorin...
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Authors: Jia M, Xiong Y, Li M, Mao Q Abstract Chemotherapy is critical for the treatment of hepatocellular carcinoma (HCC). Despite the pro-apoptotic effects of corosolic acid (CA) treatment, its underlying mechanism is not completely clear. The aim of this study was to determine the molecular mechanism of CA in HCC treatment. MTT assay was used to determine the IC50 of CA. Immunoprecipitation and immunofluorescence were used to detect the interaction between and subcellular localization of Yes-associated protein (YAP) and mouse double minute 2 (MDM2). In addition, in vivo xenotransplantation was performed to asses...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
In the original publication, in Abstract, the second sentence of Results has been incorrectly published as.
Source: Surgery Today - Category: Surgery Source Type: research
British Journal of Cancer, Published online: 31 March 2020; doi:10.1038/s41416-020-0816-8Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Minato S, Miyazawa H, Kitano T, Shindo M, Ito K, Ueda Y, Hirai K, Hoshino T, Ookawara S, Morishita Y Abstract A 49-year-old woman developed eosinophilic peritonitis 2 months after starting continuous ambulatory peritoneal dialysis because of congenital right kidney hypoplasia and chronic glomerulonephritis. This was shown to have been induced by sucroferric oxyhydroxide, an iron-based phosphate binder, using a drug-induced lymphocyte stimulation test. Her eosinophilic peritonitis was improved after stopping the administration of sucroferric oxyhydroxide without providing any immunosuppressive agents. P...
Source: Peritoneal Dialysis International - Category: Urology & Nephrology Tags: Perit Dial Int Source Type: research
Conclusions: The expression of ERCC1 and NF- κ B give a worse prognosis for relapse, and only ERCC1 had an influence on the overall survival of TGCT patients treated with platinum-based chemotherapy. These may represent markers that predict poor clinical outcome and response to cisplatin.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
More News: Anemia | Autoimmune Disease | Chemotherapy | Glomerulonephritis | Internal Medicine | Lessons | Lupus | Nephrotic Syndrome | Prednisone | Proteinuria | Thrombocytopenia | Urology & Nephrology